Europe Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

The Europe epilepsy market was valued at US$ 1.94 billion in 2022 and is expected to reach US$ 2.62 billion by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.

Increasing Investments in Development of Epilepsy Therapies Drive Europe Epilepsy Market

The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.

• In March 2023, the Swedish government decided to commission Vinnova, Sweden’s innovation agency, a total of US$ 7.7 million (80 million SEK) to establish a national innovation cluster for commercialization, skills development, and production capacity build-up for cell therapies and other advanced treatments such as gene therapy.
• In November 2022, Scientists at Aston University in the UK, working on a project to develop new drug treatments to prevent the beginning of childhood epilepsy, were awarded US$ 2.4 million (£2 million) to discover the disease mechanism in the brain and the ways of epilepsy prevention. This three-year project funded by the Medical Research Council is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, combined with Bristol University and Jazz Pharmaceuticals.
• In July 2022, Cerebral Therapeutics secured US$ 40 million in the Series C round funding to get its implanted infusion epilepsy treatment ready for phase 3 development. The funding round was led by Lynx1 Capital Management among other investors, including RA Capital Management and Perceptive Advisors. Cerebral Therapeutics intends to deliver the specified levels of valproate to the central nervous system without causing weight gain, which was witnessed in subjects of oral formulation studies.
• In November 2021, Neurava, a startup located in Indiana, received over US$ 0.65 million in seed funding led by Elevate Ventures with participation from Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures, and angel investors. The company is working on the development of a wearable device to monitor and alert users about the approaching risk of sudden, unexpected death caused by epilepsy.
• In June 2021, Neurona Therapeutics Inc., a biotherapeutics company, successfully completed a US$ 41.5 million financing to advance the company’s pipeline of wholly owned, off-the-shelf cell therapies for various indications, including NRTX-1001 (a Phase 1/2a clinical study), an inhibitory neuronal cell therapy for the treatment of chronic focal epilepsy.

Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.

Europe Epilepsy Market Overview

The European epilepsy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy market. The European epilepsy market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Market Segmentation

The Europe epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Europe epilepsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Europe epilepsy market.